Recently developed in vitro technology was used to define the function of a previously uncharacterized STX11 mutation L135P present in a patient with atypical FHL. The results confirmed the FHL diagnosis and enabled clinicians to proceed with assurance to hematopoietic stem cell transplantation.
Noori et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: